Model-based analysis for the population pharmacokinetics of iberdomide and its major active metabolite in healthy subjects and patients with relapsed and refractory multiple myeloma.

Cheng, Yiming; Xue, Yongjun; Chen, Lu; Masin, Mark; Maciag, Paulo; Peluso, Teresa; Zhou, Simon; Li, Yan

Cheng, Yiming; Xue, Yongjun; Chen, Lu; Masin, Mark; Maciag, Paulo; Peluso, Teresa; Zhou, Simon; Li, Yan.

Afiliação

Cheng Y; Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Princeton, NJ, USA.
Xue Y; Non-Clinical Research & Development, Bristol Myers Squibb, Princeton, NJ, USA.
Chen L; Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Princeton, NJ, USA.
Masin M; Global Drug Development, Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland.
Maciag P; Global Drug Development, Bristol Myers Squibb, Princeton, NJ, USA.
Peluso T; Global Drug Development, Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland.
Zhou S; Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Princeton, NJ, USA.
Li Y; Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Princeton, NJ, USA.

Br J Clin Pharmacol ; 89(1): 316-329, 2023 01.

Article em En | MEDLINE | ID: mdl-35981078

Assuntos

Mieloma Múltiplo; Humanos; Voluntários Saudáveis; Índice de Massa Corporal; Peso Corporal; Modelos Biológicos

Palavras-chave

iberdomide; metabolite; multiple myeloma; population pharmacokinetics

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google